Whalesbook
Vivimed Labs Ltd has officially informed stock exchanges that it does not meet the criteria to be classified as a 'Large Corporate (LC)' under SEBI's framework.
This declaration, made on April 6, 2026, means the company is not subject to specific SEBI regulations concerning fund-raising via debt securities that are mandated for LCs.
Filing Confirms Non-Large Corporate Status
Vivimed Labs Limited submitted a declaration to the BSE and NSE on April 6, 2026. It explicitly states the company is outside the definition of a 'large corporate entity' as per SEBI Circular No. SEBI/HO/DDHS/CIR/P/2018/144, dated November 26, 2018.
The company requested that the exchanges take this statement on record.
Why This Matters
SEBI's 'Large Corporate' framework, introduced to deepen the bond market, imposes specific borrowing and disclosure obligations on identified entities. By declaring it is not an LC, Vivimed Labs clarifies that these particular regulatory requirements do not apply to it. This is significant given the company's financial condition and recent legal entanglements.
SEBI's Large Corporate Framework Explained
SEBI introduced the 'Large Corporate' framework through Circular SEBI/HO/DDHS/CIR/P/2018/144 on November 26, 2018. This framework applies to listed entities (excluding banks) that have listed securities and outstanding long-term borrowings of Rs 100 crore or more (this threshold was later revised to Rs 1000 crore) coupled with a credit rating of 'AA' or above.
Entities identified as LCs are mandated to raise at least 25% of their incremental borrowings through debt securities. This aims to channel more corporate financing through the debt market. The classification and associated obligations became effective from April 1, 2019.
What Changes Now
Vivimed Labs, by not being classified as an LC, is exempt from the specific regulatory mandate to raise a portion of its incremental borrowings via debt securities under the SEBI circular. Consequently, it avoids the associated disclosure requirements related to this framework.
Risks to Watch
Vivimed Labs has been facing significant financial headwinds. In Q3 FY26, its net loss widened to ₹165.66 million from ₹74.45 million YoY, with revenue dropping to ₹116.31 million from ₹186.59 million. The company's auditors have also issued qualified opinions, citing unprovided interest charges and ongoing forensic audit evaluations.
Furthermore, the company is involved in a Central Bureau of Investigation (CBI) case registered in November 2025 concerning alleged bank fraud, though an interim stay has been obtained from the High Court. Analysts have noted high leverage and negative EBITDA, contributing to a 'Strong Sell' rating on technical grounds.
Peer Comparison
Vivimed Labs is not alone in making such a declaration. Prime Fresh Limited also officially communicated on April 6, 2026, to the BSE that it does not qualify as a 'Large Corporate (LC)' under the same SEBI circular, thus finding the related disclosure requirements non-applicable to its operations.
What to Track Next
Investors will closely monitor Vivimed Labs' ongoing financial performance and its ability to navigate the existing legal proceedings involving the CBI. The company's compliance with other SEBI regulations and its strategy for operational and financial recovery will be key points of interest.
Any further updates on the CBI investigation, court proceedings, and the company's auditor's reports will be critical.